Sangjin Lee, MD
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MINPI 1013050764
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 59.3% of the total. Reporting peaked in 2019 at $9,787 and has fallen 90.6% since, to $923 in 2025.
Across 148 payments — averaging $165.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$15K
- Medtronic$6K
- Ancora Heart, Inc.$2K
- Cvrx, Inc.$447
- Pfizer$259
- Abiomed$220
- plus $748 from 13 others
Across 1 payment — averaging $3565.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$4K
What the payments were for
- Consulting fees$8,45034%
- Travel & lodging$9,69040%
- Food & beverage$6,38626%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 77 | $14,551 |
| Medtronic(2 entities) | 28 | $6,168 |
| Ancora Heart, Inc. | 6 | $2,133 |
| Cvrx, Inc. | 5 | $447 |
| Pfizer | 7 | $259 |
| Abiomed | 4 | $220 |
| AstraZeneca | 3 | $147 |
| Edwards Lifesciences | 1 | $135 |
| Boehringer Ingelheim | 2 | $135 |
| Livanova USA, Inc. | 1 | $79 |
| Novartis | 4 | $57 |
| Atricure, Inc. | 2 | $42 |
| Merck | 2 | $35 |
| Chiesi USA, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$9,184
- AccuCinch$2,111
- HeartMate 3 Left Ventricular Assist Device$1,744
- HeartMate 3 Left Ventricular Dev$1,488
- Barostim Neo System$414
- CardioMEMS HF System$280
- HeartWare HVAD$275
- MitraClip$168
- CARDIOMEMS$166
- PASCAL$135
- Micra$128
- Impella$125
- JARDIANCE$120
- WAINUA$118
- VYNDAQEL$115
How this compares
$24,526 in reported general payments places this provider in the 85th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 135 | $2,996,457 |
| EntrestoSacubitril/Valsartan | 223 | $257,593 |
| FarxigaDapagliflozin Propanediol | 165 | $153,151 |
| EliquisApixaban | 130 | $132,345 |
| JardianceEmpagliflozin | 96 | $110,473 |
| XareltoRivaroxaban | 15 | $17,535 |
| Metoprolol Succinate | 179 | $4,409 |
| Torsemide | 166 | $3,942 |
| Spironolactone | 232 | $2,272 |
| Potassium Chloride | 46 | $2,090 |
| Atorvastatin Calcium | 111 | $1,890 |
| Carvedilol | 121 | $1,608 |
| Eplerenone | 13 | $1,148 |
| Isosorbide Dinitrate | 15 | $1,091 |
| Amiodarone Hcl | 43 | $935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $259 | $3,128,802265 claims |
| NovartisEntresto | $57 | $257,593223 claims |
| AstraZenecaFarxiga | $147 | $153,151165 claims |
| Boehringer IngelheimJardiance | $135 | $110,47396 claims |
| Johnson & JohnsonXarelto | $21 | $17,53515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
Other advanced heart failure and transplant cardiology in Grand Rapids
- David FerminGrand Rapids$105K
- Michael DickinsonGrand Rapids$80K
- Matthew GonzalezGrand Rapids$22K
- Renzo Loyaga-RendonGrand Rapids$5K
- Ryan GrayburnGrand Rapids$4K
- Milena JaniGrand Rapids$3K
- Jennifer CowgerDetroit$165K
- Thomas CascinoAnn Arbor$39K
- Keith AaronsonAnn Arbor$22K
- Waleed Al-DarziDetroit$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.